2Johnston SR.New strategies in estrogen receptor-positive breast cancer[J].Clin Cancer Res,2010,16(7):1979-1987.
3Guarneri V,Barbieri E,Dieci MV,et al.Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer[J].Cancer Treat Rev,2010,36(3):$62-$66.
4Giampaglia M,Chiuri VE,Tinelli A,et al.Lapatinib in breast cancer:clinical experiences and future perspectives[J].Cancer Treat Rev,2010,36(3):S72-S79.
5Carpini JD,Karam AK,Montgomery L.Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast,ovarian,and cervical cancer[J].Angiogenesis,2010,13 (1):43-58.
6The ATAC Trialists Group.Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer:100-month analysis of the ATAC trial[J].Lancet Oncol,2008,9(1):45-53.
7Coates AS,Keshaviah A,Thurlimann B,et al.Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausai women with endocrine-responsive early breast cancer:update of study BIG 1-98[J].J Clin Oncol,2007,25(5):486-492.
8Coombes RC,Kilbum LS,Snowdon C,et al.Survival and safety of exemestane versus tamoxifen after 2-3 years'tamoxifen treatment (Intergroup Exemestane Study):a randomized controlled trial[J].Lancet,2007,369(9561):559-570.
9Boccardo F,Rubagotti A,Puntoni M,et al.Switching to anastrozole versus continued tamoxifen treatment of early breast cancer:preliminary results of the Italian Tamoxifen Anastrozole Trial[J].J Clin Oncol,2005,23(22):5138-5147.
10Jakesz R,Jonat W,Gnant M,et al.Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years'adjuvant tamoxifen:combined results of ABCSG trial 8 and ARNO 95 trial[J].Lancet,2005,366(9484):455-462.
